The obesity epidemic affecting our youth requires innovative approaches, and GLP-1 RAs may represent an important advancement in our therapeutic armamentarium
In this respect, GLP-1s have an added benefit for MASH patients since they have been shown to reduce the rate of major cardiovascular events, including strokes and heart attacks
Claim 21 and related dependent claims: fixed 2.5 mg starting dose and duration minima with explicit HbA1c and weight targets Claim 21 specifies: first once-weekly dose: 2.5 mg for four weeks, titration: increase by 2.5 mg increments, each increased dose: administered for at least four weeks, maintenance: 5, 10, or 15 mg once weekly to improve glycemic control
Londoo-Lemos * Vice-Rectory of Research, Physiotherapy Program, Manuela Beltrn University, Bogot D.C, Colombia Received date: January 21, 2018
Important safety considerations include an increased risk of hypoglycemia when used with insulin or sulfonylureas, and a boxed warning about thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2)
